|
|
|
|
|
Oxymorphone
drug data and news
Oxymorphone drug data, resources, and news articles (when available). Onconews.org provides news on cancer research. This section, which includes profiles on medicines that may or not be cancer-related is in beta form. If things run smoothly we will be releasing a new format late in the summer of 2006.
|
| Generic name | Oxymorphone | ||
| Brand Names/Synonyms | Dihydrohydroxymorphinone; Dihydroxymorphinone; Numorphan; Oximorphonum; Oxymorphine; Oxymorphone | ||
| Indication | For the treatment of moderate-to-severe pain | ||
| Sponsored links | Description | Not Available | |
| Pharmacology | Oxymorphone is a semi-synthetic opioid substitute for morphine. It is a potent analgesic. Opioid analgesics exert their principal pharmacologic effects on the CNS and the gastrointestinal tract. The principal actions of therapeutic value are analgesia and sedation. Opioids produce respiratory depression by direct action on brain stem respiratory centers. The mechanism of respiratory depression involves a reduction in the responsiveness of the brain stem respiratory centers to increases in carbon dioxide tension and to electrical stimulation. | ||
| Mechanism Of Action | Oxymorphone interacts predominantly with the opioid mu-receptor. These mu-binding sites are discretely distributed in the human brain, with high densities in the posterior amygdala, hypothalamus, thalamus, nucleus caudatus, putamen, and certain cortical areas. They are also found on the terminal axons of primary afferents within laminae I and II (substantia gelatinosa) of the spinal cord and in the spinal nucleus of the trigeminal nerve. | ||
| Oxymorphone News (When available) |
| ||
| Dosage Forms | LIQUID | ||
| Drug_Category | Narcotics; Adjuvants; Analgesics; Opiate Agonists; ATC:N02A | ||
| Absorption | Not Available | ||
| Interactions |
Interactions for Oxymorphone: The concomitant use of other CNS depressants including sedatives, hypnotics, tranquilizers, general anesthetics, phenothiazines, other opioids, tricyclic antidepressants, monoamine oxidase (MAO) inhibitors, and alcohol may produce additive CNS depressant effects. When such combined therapy is contemplated, the dose of one or both agents should be reduced. Anticholinergics or other medications with anticholinergic activity when used concurrently with opioid analgesics may result in increased risk of urinary retention and/or severe constipation, which may lead to paralytic ileus. It has been reported that the incidence of bradycardia was increased when oxymorphone was combined with propofol for induction of anesthesia. In addition, CNS toxicity has been reported (confusion, disorientation, respiratory depression, apnea, seizures) following coadministration of cimetidine with opioid analgesics; no clear-cut cause and effect relationship was established. | ||
| Toxicity | Not Available | ||
| Organisms Affected | Humans and other mammals | ||
| Chemical IUPAC Name | Not Available | ||
| Chemical Formula | C17H19NO4 | ||
| Molecular Weight | 301.337 g/mol | ||
| Smiles String | CN1CCC23C4C(=O)CCC2(C1CC5=C3C(=C(C=C5)O)O4)O | ||
| Melting Point | 248-249 °C | ||
| Water Solubility | 2.4E+004 mg/L | ||
| State | Solid | ||
| LogP/Hphobicity | 0.904 | ||
| Isoelectric Point | 8.17 | ||
| Biotransformation | Not Available | ||
| Half Life | 1.3 (+/-0.7) hours | ||
| Protein Binding [%] | Not Available | ||
| RxList Link | RXlist | ||
| Sponsored links | |||
| Drug Reference |
http://www.drugs.com/cons/Oxymorphone.html http://www.rxlist.com/cgi/generic2/oxymorphone.htm | ||
| Drug Type | Approved Drug | ||
| Accession No | APRD00158 | ||
| CAS Registry Number | 76-41-5 | ||
| KEGG Compound ID | C08019 | ||
| PubChem ID | SID:10219 | ||
| PharmGKB ID | PA450748 | ||
| SwissProt ID | Not Available | ||
| GenBank ID | Not Available | ||
| Drug ID Number [DIN] | 1916505 |
|
Home | About | Cancers | Treatment | Medications Copyright onconews.org 2005. All Rights Reserved. |